buran und MfG
Anzeige
Meldung des Tages: Silber entdeckt den zweiten Werttreiber dieses Kupferprojekts
ab Augusto Ticker MARINUS
Beiträge:
56
Zugriffe: 16.140 / Heute: 2
Zugriffe: 16.140 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +124,10%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +60,22%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +55,53%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +54,35%
Datum Erster Hoch Tief Schluss Stücke Volumen
08.08.14 8,00 8,04§8,00 8,02 $ 17.500 140 T
GrB
08.08.14 8,00 8,04§8,00 8,02 $ 17.500 140 T
GrB
Preis pro share 8,02 $ Schleife 200 spread 0,25% buran und MfG und ticker schei
Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
Preis pro Sternchen 8,04 $ Schleife 200 spread 0,50% buran und MfG und Himmel Mond und Sterne wir haben Ticker Sternchen Laternen allzu gerne ..::hopshops HALLO
::::::::::::::::::::: 8,05 $ +0,37% +0,03 $
In Euro: 6,0236 € | Nasdaq, 11.08.14::::::::::::::::: HEISS
In Euro: 6,0236 € | Nasdaq, 11.08.14::::::::::::::::: HEISS
Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
Preis pro oooh cheri cheri 8,05 $ Schleife 4.500 spread 0,63% buran und MfG und oooooooh cheri cheri ..::hopshops HALLO
Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB
Preis pro MARINUS 8,02 $ Schleife 100 spread 0,25% buran und MfG und Ticker Dir Ein ..::hopshops HALLO
$ 8.00 -0.08 (0.93%)
Day High: 8.08
Day Low: 8.00
Volume: 8,000 3:59 PM ET on
Aug 13, 2014
www.marinuspharma.com/#!investors/c242w
Day High: 8.08
Day Low: 8.00
Volume: 8,000 3:59 PM ET on
Aug 13, 2014
www.marinuspharma.com/#!investors/c242w
MARINUS PHARMACEUTICALS, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock at a public offering price of $8.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "MRNS" on July 31, 2014. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 843,750 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on August 5, 2014, subject to customary closing conditions.
Stifel and JMP Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager and Janney Montgomery Scott is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 31, 2014. The offering will be made only by means of a prospectus, copies of which may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery St., 10th Floor, San Francisco, CA 94111, or by calling (415) 835-8985.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Edward F. Smith
Vice President, CFO, Secretary and Treasurer
Marinus Pharmaceuticals, Inc.
(203) 315-0566
esmith@marinuspharma.com
ir.marinuspharma.com/releasedetail.cfm?ReleaseID=863384
NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock at a public offering price of $8.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "MRNS" on July 31, 2014. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 843,750 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on August 5, 2014, subject to customary closing conditions.
Stifel and JMP Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager and Janney Montgomery Scott is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 31, 2014. The offering will be made only by means of a prospectus, copies of which may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery St., 10th Floor, San Francisco, CA 94111, or by calling (415) 835-8985.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Edward F. Smith
Vice President, CFO, Secretary and Treasurer
Marinus Pharmaceuticals, Inc.
(203) 315-0566
esmith@marinuspharma.com
ir.marinuspharma.com/releasedetail.cfm?ReleaseID=863384
MARINUS PHARMACEUTICALS, INC. ENTERS INTO USE AGREEMENT WITH CYDEX PHARMACEUTICALS, INC. FOR USE OF CAPTISOL(R) FOR GANAXOLONE IVir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715
- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly owned subsidiary of Ligand Pharmaceutical Incorporated, for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous (IV) dose form of ganaxolone with Captisol.ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715
step towards optimizing our IV formulation of ganaxolone for inpatient, acute care treatment situations," said Christopher M. Cashman, President and CEO of Marinus Pharmaceuticals, Inc. "Ganaxolone IV is planned to be available for human clinical testing next year and complements our existing capsule and liquid suspension dose forms presently in the clinic."ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715
is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and has been designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and plans to initiate a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABAA receptors. For additional information, please visit the Company's website at www.marinuspharma.com.ir.marinuspharma.com/...ReleaseID=865715
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including optimizing a product's formulation and the clinical trial testing schedule. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission. ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715
www.marinuspharma.com/#!stock-information/c7pm GrB
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Marinus Pharmaceuticals Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 43 | Marinus Pharmaceuticals Buy KZ 16 USD | Balu4u | Vassago | 30.12.24 14:04 | |
| 55 | ab Augusto Ticker MARINUS | buran | buran | 25.04.21 01:13 |